Verena S. Hoffmann

PD Dr. Verena S. Hoffmann serves as Head of the DIFUTURE Analysis Group at the Institute for Medical Informatics, Biometry, and Epidemiology (IBE) within LMU Munich's Faculty of Medicine, focusing on biostatistical methodology for clinical research. Her career spans roles at Helmholtz Zentrum München and LMU's Department of Infectious Diseases, establishing her as a key figure in medical data science.

Her academic foundation includes:

• High School Diploma (2001)
• Studies in Statistics at LMU (2001-2003)
• Data Analysis and Management at University of Dortmund (2003-2006)
• Interdisciplinary studies in Political Science, Statistics, and Computer Science at LMU (2005-2008)
• Promotion (PhD) in 2013

Dr. Hoffmann specializes in clinical trial design, prognostic modeling, and systematic reviews with meta-analyses, pioneering distributed analysis frameworks like DataSHIELD for privacy-preserving multi-institutional research. Her work bridges oncology (chronic myeloid leukemia registries) and diabetes research (risk prediction for pediatric type 1 diabetes), emphasizing real-world evidence generation.

Analysis of her 2013-2019 publications reveals consistent focus on large-scale registry studies (e.g., EUTOS for CML) and methodological innovation in distributed analytics. She integrates survival analysis with population health metrics across oncology, cardiology, and geriatrics, demonstrating expertise in translating complex statistical models into clinical decision tools.

As leader of the DIFUTURE consortium's analysis arm, she directs projects including Multiple Sclerosis and Stroke use cases, alongside the CORIMO initiative for pandemic risk monitoring. Her grant-funded work involves cross-institutional collaboration with Helmholtz Association partners, securing infrastructure for national medical data integration.

Her DIFUTURE Analysis Group develops secure computational pipelines for federated data analysis, partnering with German university hospitals to advance precision medicine through privacy-compliant analytics—particularly impactful in rare disease research and public health surveillance.